Project Grant R21EY039420
- The National Eye Institute awarded The Trustees of The University of Pennsylvania $719,199 on August 5, 2026, under the Vision Research program (CFDA 93.867) to advance understanding of retinal ganglion cell and optic nerve regeneration following injury and optic neuropathies. The research will employ single-cell CRISPR screening (perturb-seq) to systematically identify genes and gene combinations whose suppression most effectively promotes retinal ganglion cell and optic nerve regeneration...
- The National Eye Institute awarded the University of Pittsburgh $2,077,596 on September 30, 2025, under the Vision Research program (CFDA 93.867) to conduct electrophysiological and computational research on sensorimotor processing in the oculomotor system, specifically examining how the superior colliculus processes moving targets and generates interceptive saccades. The research addresses gaps in understanding how the nervous system estimates the future location of moving objects to guide...
- The National Eye Institute awarded The Johns Hopkins University $698,999 on July 1, 2026, under the Vision Research program (CFDA 93.867) to conduct research on mechanisms of functional retinal engraftment by transplanted retinal ganglion cells for optic neuropathies including glaucoma. The project addresses the death of retinal ganglion cells (RGCs), which transmit visual information from the eye to the brain. While existing treatments slow vision loss in some progressive optic neuropathies, no...
- The National Eye Institute awarded The University of Texas Southwestern Medical Center $456,500 on July 1, 2026, under the Vision Research program (CFDA 93.867, Assistance Listing) for spatial molecular profiling of optic nerve injury and assessment of extracellular matrix (ECM) proteins. The research examines why regenerated retinal ganglion cell (RGC) axons fail to reach the brain after optic nerve injury, instead following circuitous pathways within fibrotic scars—a phenomenon the...
- The National Eye Institute awarded the University of Pennsylvania $674,423 on September 1, 2026, under the Vision Research program (CFDA 93.867) to investigate the role of retinal microsomal triglyceride transfer protein (MTP) in vision and lipid homeostasis. The research examines how MTP regulates the assembly and secretion of apoprotein B-containing lipoproteins in the retinal pigment epithelium (RPE), which transport lipids and prevent pathologic lipid accumulation linked to retinal...
- The National Institutes of Health National Eye Institute awarded the University of Connecticut Health Center $416,250 on April 15, 2026, under the Vision Research program (CFDA 93.867) to investigate NFE2L3-regulated mechanisms of retinal ganglion cell neuroprotection and optic nerve axon regeneration. The research examines molecular mechanisms through which the NFE2L3 protein regulates regeneration of damaged optic nerve axons in retinal ganglion cells. The project uses established animal...
- The National Eye Institute awarded the University of California, San Diego $701,576 on July 1, 2026, under the Vision Research program (CFDA 93.867) to explore retinal ganglion cell endogenous repair after injury using engineered human pluripotent stem cells. The research uses human pluripotent stem cell-derived 3D retinal organoids as a model to investigate glia-to-neuron repair mechanisms in the retina. Work focuses on how transcription factors enable Müller glia to respond to injury and...
- The National Eye Institute, part of the Department of Health and Human Services, awarded $458,288 to the University of Washington on May 1, 2026, under the Vision Research program (CFDA 93.867, Assistance Listing designation Project Grant). The award funds research into stimulation of regeneration in the human retina. The investigator team will test whether expressing the proneural regulatory gene ASCL1 in Müller glia can induce regeneration of retinal neurons in human tissue and adult non-human...
- The National Eye Institute awarded the University of Pittsburgh $679,650 on June 1, 2026, under the Vision Research program (CFDA 93.867) to conduct in vivo imaging of the immune response in human uveitis, linking cellular-level optical biomarkers to the immune environment of the living eye. The project will develop and validate adaptive optics ophthalmoscopy (AOO) methods to assess immune responses in posterior uveitis—inflammation affecting the retina and choroid—in real time within living...
- The National Eye Institute awarded Baylor College of Medicine $1.6 million on September 30, 2025, under the Vision Research program (CFDA 93.867) to conduct basic research on Hippo and Wnt pathway regulation of mammalian Müller glial cell reprogramming and proliferation as a strategy for retinal regeneration in glaucoma, macular degeneration, diabetic retinopathy, and traumatic retinal injury. The research employs genetic loss- and gain-of-function experiments, fate mapping, and single-cell...
The National Eye Institute awarded the University of Pittsburgh $433,324 under the Vision Research program (CFDA 93.867) on September 1, 2026, to develop next-generation microfluidic platforms for high-throughput screening of axon growth-promoting compounds as potential regeneration therapies for glaucoma and optic neuropathies. The project focuses on addressing limitations in conventional axon growth assays by engineering microfluidic devices that enable defined chemoattractant gradients, single-neuron tracking, and spatiotemporal resolution with minimal reagent use and reduced cell input requirements compared to existing platforms. The research builds on prior identification of TPPP3 as an axon regeneration promoter and explores combination therapies pairing gene therapy approaches, such as adeno-associated virus vectors, with pharmaceutical partners to enhance retinal ganglion cell regeneration and restore visual function following optic nerve injury. Work is performed at the University of Pittsburgh in Pittsburgh, Pennsylvania, with a period of performance from September 1, 2026, through August 31, 2028. This is a Project Grant, an investigator-initiated award supporting exploratory research in early-stage or high-risk scientific directions aligned with NEI priorities in vision disease prevention and treatment.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $433.3k | 8/24/26 |